A carregar...
Personalized drug combinations to overcome trastuzumab resistance in HER2-positive breast cancer
HER2-positive (HER2+) breast cancer accounts for 18%–20% of all breast cancer cases and has the second poorest prognosis among breast cancer subtypes. Trastuzumab, the first Food and Drug Administration-approved targeted therapy for breast cancer, established the era of personalized treatment for HE...
Na minha lista:
| Publicado no: | Biochim Biophys Acta |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2014
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4261073/ https://ncbi.nlm.nih.gov/pubmed/25065528 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.bbcan.2014.07.007 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|